---
title: "諾和諾德簽署 21 億美元許可協議"
description: "10 月 15 日，丹麥製藥商諾和諾德和美國生物技術公司 Omeros 宣佈，雙方已簽署一項價值高達 21 億美元的許可協議，諾和諾德將獲得 Omeros 正在研發的一款用於治療罕見血液和腎臟疾病的藥物。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261291274.md"
published_at: "2025-10-15T15:18:53.000Z"
---

# 諾和諾德簽署 21 億美元許可協議

> 10 月 15 日，丹麥製藥商諾和諾德和美國生物技術公司 Omeros 宣佈，雙方已簽署一項價值高達 21 億美元的許可協議，諾和諾德將獲得 Omeros 正在研發的一款用於治療罕見血液和腎臟疾病的藥物。

10 月 15 日，丹麥製藥商諾和諾德和美國生物技術公司 Omeros 宣佈，雙方已簽署一項價值高達 21 億美元的許可協議，諾和諾德將獲得 Omeros 正在研發的一款用於治療罕見血液和腎臟疾病的藥物。

### Related Stocks

- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | [Link](https://longbridge.com/zh-HK/news/270794581.md) |
| Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground | Novo Nordisk CEO Mike Doustdar announced that 1.5 million people in the U.S. are using compounded GLP-1 weight-loss drug | [Link](https://longbridge.com/zh-HK/news/272307926.md) |
| SolarEdge Technologies Q4 Earnings Report: What Investors Need to Know | SolarEdge Technologies (NASDAQ:SEDG) reported Q4 earnings on February 18, 2026, beating estimates by 64.1% with an EPS o | [Link](https://longbridge.com/zh-HK/news/276229789.md) |
| Ingalls & Snyder LLC Sells 6,891 Shares of Oracle Corporation $ORCL | Ingalls & Snyder LLC reduced its stake in Oracle Corporation (NYSE:ORCL) by 12.9% in Q3, selling 6,891 shares, leaving t | [Link](https://longbridge.com/zh-HK/news/276218440.md) |
| BUZZ-Hecla Mining up after upbeat results, Casa Berardi sale announcement | Hecla Mining shares rose 5.6% premarket to $22.43 following a strong Q4 report, with revenue up 83% year-over-year to $4 | [Link](https://longbridge.com/zh-HK/news/276217251.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。